HK Stock Market Move | AIM VACCINE (06660) rose more than 8% during trading hours, and the serum-free iterative rabies vaccine received acceptance for registration for listing.

AIM VACCINE (06660) rose more than 8% during trading, and as of the time of writing, it was up 5.76% at 3.49 Hong Kong dollars, with a trading volume of 2.8511 million Hong Kong dollars. In terms of news, AIM VACCINE announced that the company's serum-free iterative rabies vaccine has been granted a registration approval by the National Medical Products Administration, with acceptance number: CXSS2500044. In addition, the company's wholly-owned subsidiary, Aimee Honor (Ningbo) Biopharmaceutical Co., Ltd., has recently obtained a production license for the corresponding serum-free iterative rabies vaccine. Currently, there is no approved serum-free rabies vaccine on the global market, and this product is expected to be the first one to be approved. The announcement also stated that as the world's second-largest supplier of rabies vaccines, the company has completed the construction of a serum-free iterative rabies vaccine workshop that meets international standards, and has completed commercial-scale verification production. It has the capability to produce the product on a large scale, and once approved, it can quickly enter the market. The future approval and sale of this vaccine are expected to significantly increase the company's performance.